Acinetobacter baumannii complex, national laboratory-based surveillance in South Africa, 2017 to 2019

Olga Perovic¹,²,*; Adrian Duse²; Vindana Chibabhai²,³; Marianne Black²,³; Mohamed Said⁴,⁵; Elizabeth Prentice⁶; Jeannette Wadula²,⁷; Yesholata Mahabeer⁸,⁹; K. Swe Swayne Han⁸,⁹; Ruth Mogokoteng¹; Wilhelmina Strasheim¹; Michelle Lowe¹; Sabelle Jallow¹,²; Husna Ismail¹; for GERMS-SA

¹ Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for Communicable Diseases, Johannesburg, South Africa, ² Division of Clinical Microbiology and Infectious Diseases, Faculty of Health Science, School of Pathology of the University of the Witwatersrand and the National Health Laboratory Service (NHLS), Johannesburg, South Africa, ³ National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Microbiology laboratory, Johannesburg, South Africa, ⁴ Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa, ⁵ National Health Laboratory Services, Tshwane Academic Division, Pretoria, South Africa, ⁶ Department of Medical Microbiology University of Cape Town and the National Health Laboratory Services, Groote Schuur Hospital, Cape Town, South Africa, ⁷ Chris Hani Baragwanath Academic Hospital, Soweto, South Africa, ⁸ Department of Medical Microbiology, National Health Laboratory Service, Inkosi Albert Luthuli Central Hospital, Durban, South Africa, ⁹ School of Laboratory Medicine and Medical Sciences, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa

¶ Membership of the GERMS-SA is listed in the Acknowledgments.

* olgap@nicd.ac.za

Abstract

Objective

We aimed to provide an analysis of A. baumannii complex (ABC) isolated from blood cultures in South Africa.

Materials and methods

ABC surveillance was conducted from 1 April 2017 to 30 September 2019 at 19 hospitals from blood cultures of any age and sex. Organism identification was performed using the MALDI-TOF MS and antimicrobial susceptibility testing (AST), MicroScan Walkaway System. We confirmed colistin resistance with Sensititre, FRCOL panel, and selected for whole-genome sequencing.

Results

During the study period, we identified 4822 cases of ABC, of which 2152 cases were from 19 enhanced surveillance sites were reported during the enhanced surveillance period (1 August 2018 to 30 September 2019). Males accounted for 54% (2611/4822). Of the cases with known age, 41% (1968/4822) were infants (< 1-year-old). Seventy-eight percent (1688/2152) of cases had a known hospital outcome, of which 36% (602/1688) died. HIV status was known for 69% (1168/1688) of cases, and 14% (238/1688) were positive. Eighty-two
percent (1389/1688) received antimicrobial treatment in admission. Three percent (35/1389) of cases received single colistin. Four percent (75/2033) were resistant to colistin. At least 75% of the isolates (1530/2033) can be classified as extensively drug-resistant (XDR), with resistance to most antibiotics except for colistin. The majority, 83% (20/24), of the colistin-resistant isolates were of the sequence type (ST) 1. Resistance genes, both plasmid- and chromosomal-mediated were not observed. Although all isolates had, nine efflux pump genes related to antimicrobial resistance.

**Conclusion**

Our surveillance data contributed to a better understanding of the natural course of *A. baumannii* disease, the patient characteristics among infants, and the level of resistance. At least two-thirds of the isolates were extensively drug-resistant, and four percent of isolates were resistant to colistin.

**Background**

Antimicrobial resistance (AMR) threatens the efficacy of the successful treatment of infectious diseases and has public health implications at local, national, and global levels. AMR frequently occurs in microorganisms that are likely to be transmitted both, in the community and healthcare settings. *Acinetobacter* is an environmental organism that spreads efficiently in healthcare facilities and is a frequent cause of outbreaks.

According to the WHO priority pathogens list, the ESKAPE (*Enterococcus* spp., *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Escherichia coli* or *Enterobacter* spp.) are the most common healthcare-associated (HA) organisms with high rates of antibiotic resistance. In response, the National Institute for Communicable Diseases (NICD) established a laboratory-based antimicrobial resistance surveillance (LARS) program for ESKAPE organisms from sentinel tertiary hospital sites across South Africa.

While many species of *Acinetobacter* can cause human disease, *A. baumannii*, *A. pittii*, *A. nosocomialis*, and *A. calcoaceticus* account for about 80% of reported infections; making *Acinetobacter baumannii* complex (ABC) one of the most clinically important of HA pathogens [1].

The reservoir of ABC is soil and water, but it can be found on the skin of healthy people, especially hospitalized patients, and may survive in the healthcare environment for several days [2]. ABC may also colonize patients without causing infection or symptoms, such as in post-surgical wounds, catheter ports, tracheostomy sites, or open wounds. Clinical manifestations in patients with ABC range from mild to severe infections. Infections with ABC can cause bacteraemia, nosocomial pneumonia, meningitis, urinary tract infection, central venous catheter-related infection, and wound infection. ABC infection typically occurs in critically ill children and adult patients and can cause or contribute to the death [3].

The increasing prevalence of multidrug-resistant (MDR), extensive drug-resistant (XDR), and pan drug-resistant ABC [5] resulting in severely
limited available treatment options [6]. ABC can also be classified as carbapenem-resistant *A. baumannii* (CRAB); these isolates are usually multidrug-resistant thought CRAB, is listed as priority or critical number one on the WHO priority pathogens list for research and development of new antibiotics [7]. Optimal treatment should be made on a case-by-case basis by a clinician based on susceptibility testing results. XDR ABC strains remain commonly susceptible to polymyxins (colistin—polymyxin B) [8]. Combination therapy has been used with colistin, which includes tigecycline, carbapenems, or others. It has been debated whether colistin monotherapy or combination is superior. In a recent study, it was shown that colistin combination therapy with meropenem was associated with lower mortality, higher clinical and microbiological responses than colistin monotherapy, although a study done on pneumonia patients showed equivalent outcome [9, 10]. Nephrotoxicity risk was not increased with this combination treatment [10]. The emergence of colistin-resistant ABC is a major public health concern, as there are very limited novel antibiotics in the pipeline to treat XDR ABC infections [4, 11]. The mechanism of colistin resistance in ABC can be chromosomally encoded or plasmid-mediated. Among *A. baumannii* isolates, no plasmid-mediated *mcr1-5* genes have been detected from South Africa, however, the first detection of a plasmid *mcr-4.3* gene encoding colistin resistance in *A. nosocomialis* from a clinical specimen was published recently [12, 13].

Using whole-genome sequencing of multidrug-resistant ABC provides a better understanding of resistant mechanisms and elucidates the genetic relationships among strains as well as source tracking. Colistin resistance was reported as chromosomally mediated with high MIC (≥16 μg/mL), however, expression of *mcr1-10* leads to lower MIC (>2 μg/mL) or even susceptible values [14]. The colistin plasmid-mediated resistance is seldom detected in ABC as data from sequencing allows the characterization of a particular strain with the presence or absence of plasmid types.

**Study aim**

We aimed to provide a clinical and microbiological characterization of *A. baumannii* complex bacteraemia from South Africa.

**Materials and methods**

**Study design**

This was a cross-sectional study. ABC surveillance was conducted from 1 April 2017 to 31 July 2018 under GERMS-SA, which is an active, laboratory-based surveillance program. We expanded the surveillance from 1 August 2018 to 30 September 2019 at 19 enhanced hospitals located in the Free State, Gauteng, KwaZulu-Natal, and the Western Cape provinces in South Africa using surveillance officers who collected demographic and clinical information (used GERMS-SA standardized case report form) from patients who met the case definition. In addition, we conducted data check audits from routine laboratories and added missing ones to the total number of ABC.

**Case definition**

Isolation of ABC from blood cultures (BCs) of inpatients of any age and sex. Duplicate ABC isolates of the same organism obtained from the same patient within 21 days were regarded as duplicate isolates and excluded. All isolates were submitted to the Antimicrobial Resistance Reference Laboratory (AMRL) at the NICD.
Laboratory testing

Phenotypic characterization. Isolates submitted from the testing laboratories were submitted to AMRL on Dorset slopes. We confirmed organism identification of ABC isolates with matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) (Microflex, Bruker Daltonics, Germany). We performed antimicrobial susceptibility testing (AST) using the Microscan Walkaway System with the NM44 card (Beckman Coulter, USA). We confirmed colistin AST with the Sensititre® Vision® instrument (Trek Diagnostic Systems, UK) using the FRFCOL panel (Separation Scientific, SA) as an alternate manual reading. The quality control strains E. coli ESCCO 33: NCTC 13846 (colistin positive) and E. coli ESCCO 01: ATCC27853 (colistin negative) were used in all AST assays. We interpreted the AST breakpoints using the Clinical Laboratory Standards Institute (CLSI) guidelines [15]. Tigecycline interpretation was excluded, as no breakpoint values were available by CLSI.

Genotypic characterization. Genomic DNA was extracted from pure bacterial cultures grown on 5% horse blood agar plates (Diagnostic Media Products, National Health Laboratory Service (NHLS), South Africa) using a crude boiling method, and used as a template for polymerase chain reaction (PCR) amplification [16, 17]. We used previously published methods and performed multiplex PCR to identify the mcr-1 to mcr-5 genes [18].

Whole-genome sequencing (WGS). Genomic DNA was extracted for 24 isolates that had a colistin MIC ≥4 μg/mL and 14 colistin susceptible isolates (MIC ≤0.5 μg/mL) using QIAamp mini kit (Qiagen, Germany). We included 10mg/mL lysozyme (Sigma-Aldrich, USA) to ensure sufficient lysis. We measured the concentration of DNA using the Nanodrop spectrophotometer (Thermo Scientific, USA). Library preparation was done with the Nextera DNA Flex library prep kit (llumina, USA) and sequencing was performed on the MiSeq platform (llumina, USA) at a 2x300 bp read length at a 100x coverage. Raw sequencing reads were analyzed using the Jekesa pipeline (v1.0; https://github.com/FelixKrueger/TrimGalore) was used to filter the paired-end reads (Q>30 and length >50 bp). De novo assembly was performed using SPAdes v3.13 and the assembled contigs were polished using Shovill (v1.1.0; https://github.com/tseemann/shovill) [19]. The multilocus sequence typing (MLST) profiles were determined using the MLST tool (v2.16.4; https://github.com/tseemann/mlst). Assembly metrics were calculated using QUAST (v5.0.2; http://quast.sourceforge.net/quast). The Center for Genomic Epidemiology web tools (https://cge. cbs.dtu.dk/services/) were used to construct the phylogenetic tree [Newick (NWK) file]. The exported NWK file was used in Phandango, Microreact (https://microreact.org/showcase) to visualize and edit the phylogenetic tree. The Resistance Gene Identifier (RGI) tool (v5.2.0) is hosted at the web portal of the Comprehensive Antibiotic Resistance Database (CARD) (https://card.mcmaster.ca/) and ResFinder (https://cge.cbs.dtu.dk/services/ResFinder/) were used to describe the resistome of colistin-resistant A. baumannii from the assembled genome sequences [20, 21]. The sequences were submitted to Genbank with accession numbers JAKIIG000000000-JAKIP000000000.

Data management and analysis

Information on the GERMS-SA case report forms was captured on the GERMS-SA Microsoft Access Database (Microsoft Corporation, USA). We described surveillance data according to demographic and limited clinical variables. We performed statistical analysis using Stata version 15.1 (StataCorp LLC., USA). We used the Chi-square test to compare categorical variables and the Mann-Whitney Wilcoxon test to compare continuous variables. A p-value of <0.05 was considered statistically significant.
Ethical considerations

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Human Research Ethics Committee (HREC), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa (protocol number: M160667). Written consent was documented for all adult patients. For minor patients, parents or gradians gave written consent and was part of ethical approval by WITS HREC.

Results

Description of all ABC cases

During the study period (1 April 2017 to 30 September 2019), we identified 4822 cases of ABC (Fig 1).

The majority of the cases were from Gauteng province (60%; 2917/4822) followed by Kwa-Zulu-Natal (17%; 816/4822), the Free State (11%; 554/4822), and the Western Cape (11%; 523/4822) (Table 1). Males accounted for 54% (2611/4822) of cases and females accounted for 44% (2112/4822) (Table 1). About 48% (2336/4822) of cases were from the pediatric wards and 45% (2164/4822) from the adult wards (Table 1). Of the cases with known age, 41% (1968/4822) were infants (< 1-year-old) (Table 1).

Clinical characteristics of enhanced ABC cases

During the enhanced surveillance period (1 August 2018 to 30 September 2019), 2152 cases were identified. Bloodstream infections without focus accounted for 29% (628/2152) of cases. The median time from admission to bacteremia diagnosis was nine days (IQR 5–17 days). Seventy-eight percent (1688/2152) of cases had a known hospital outcome, of which 36% (602/1688) died (all-cause mortality) during hospital admission. Of the 602 cases that died, the all-
cause 14-day mortality was 86% (518/602) and all-cause 30-day mortality was 94% (566/602). The median time from admission to the outcome was 15 days (IQR 7–30 days). HIV status was known for 69% (1168/1688) of cases, of which 14% (238/1688) were HIV-positive. Eighty-two percent (1389/1688) of cases received antimicrobial treatment during admission (Table 2). Of the cases that received antimicrobial treatment, 34% (475/1389) received colistin as a definitive treatment. Treatment regimens are described in Table 3.

Characteristics of drug-resistant ABC

Of the 4822 cases of ABC, 42% (2033/4822) of isolates had a confirmed identification, of which 96% (1944/2033) were identified as *A. baumannii*, followed by 4% (78/2033) as *A. nosocomialis*. (Fig 1). *A. pittii* (9/2033) and *A. calcoaceticus* (2/2033) made up less than 1% of the total number of ABC isolates respectively (Fig 1). For the aminoglycosides, 75% (1530/2033) of isolates were resistant to amikacin and 85% (1738/2033) were resistant to gentamicin. For the third-generation cephalosporins, 82% (1676/2033) were resistant to ceftazidime; and for the carbapenems, 88% (1786/2033) of isolates were resistant to meropenem. Only four percent (75/2033) of isolates were resistant to colistin (Fig 2). At least 75% of the isolates (1530/2033) can be classified as extensively drug-resistant (XDR), being resistant to all listed relevant drug classes for *Acinetobacter* species, except for colistin [5, 22] (ref). The majority, 83% (20/24), of the colistin-resistant isolates sequenced by WGS (n = 24), were of the sequence type (ST) 1 (Fig 3). Of the colistin-resistant isolates with WGS results, the majority (13/24 or 54.1%) were

### Table 1. Characteristics of *Acinetobacter baumannii* complex (ABC) cases in South Africa from 1 April 2017 to 30 September 2019.

|                              | Number of cases (N = 4822) | Percentage (%) |
|------------------------------|-----------------------------|-----------------|
| **Province**                 |                             |                 |
| Gauteng                      | 2 917                       | 60              |
| KwaZulu-Natal                | 816                         | 17              |
| Free State                   | 554                         | 11              |
| Western Cape                 | 523                         | 11              |
| Northern Cape                | 5                           | 0.1             |
| Eastern Cape                 | 3                           | 0.06            |
| North West                   | 2                           | 0.04            |
| Limpopo                      | 1                           | 0.02            |
| Unknown                      | 1                           | 0.02            |
| **Sex**                      |                             |                 |
| Male                         | 2 611                       | 54              |
| Female                       | 2 112                       | 44              |
| Unknown                      | 99                          | 2               |
| **Ward type**                |                             |                 |
| Adult (patients aged ≥18 years) | 2164                       | 45              |
| Paediatric (patients aged <18 years) | 2336                       | 48              |
| Unknown                      | 322                         | 7               |
| **Age group**                |                             |                 |
| < 1 year                     | 1 968                       | 41              |
| 1–20 years                   | 511                         | 11              |
| 21–60 years                  | 1651                        | 34              |
| >60 years                    | 433                         | 9               |
| Unknown age                  | 259                         | 5               |

https://doi.org/10.1371/journal.pone.0271355.t001
in adults (18–64 years old), followed by infants less than one year of age (7/24 or 29.1%) (Fig 3). The level of colistin resistance was distributed in the following ranges 4–16 μg/ml in 6 (25%) isolates, 32–64 μg/ml in 10 (41.7%) isolates, and ≥128 μg/ml in 8 (33.3%) isolates (Fig 3). Antimicrobial minimum inhibitory concentration distribution was presented in Table 4.

**Molecular mechanism of resistance**

To determine the molecular mechanism of resistance to colistin, we performed PCR on all 75 colistin-resistant isolates to investigate the presence of mcr genes. All 75 isolates were PCR-

**Table 2. Clinical characteristics of Acinetobacter baumannii complex (ABC) cases with known patient outcomes in South Africa, 1 August 2018 to 30 September 2019.**

| Characteristic                        | Total (N = 1688) | Alive (N = 1086) | Died (N = 602) | p-value |
|---------------------------------------|-----------------|-----------------|---------------|---------|
| **Hospitalization**                   |                 |                 |               |         |
| Median days in hospital (IQR)         | 15 (7–30)       | 24 (13–42)      | 12 (6–24)     | <0.01   |
| Median days in hospital before BSI (IQR) | 9 (5–17)   | 10 (5–17)       | 8 (4–15)      | <0.01   |
| **Medical conditions**                |                 |                 |               |         |
| No                                    | 762             | 541 (71)        | 221 (29)      | <0.01   |
| Yes                                   | 726             | 451 (62)        | 275 (38)      |         |
| **Medical condition type**            |                 |                 |               |         |
| Diabetes mellitus                     | 95              | 54 (57)         | 41 (43)       |         |
| Respiratory diseases                  | 216             | 141 (65)        | 75 (35)       |         |
| Renal                                 | 120             | 69 (58)         | 51 (42)       |         |
| Cardiovascular                        | 28              | 15 (54)         | 13 (46)       |         |
| Malignancy                            | 72              | 36 (50)         | 36 (50)       |         |
| Other                                 | 343             | 219 (64)        | 124 (36)      |         |
| **Immune status**                     |                 |                 |               |         |
| HIV-negative                          | 930             | 634 (68)        | 296 (32)      | 0.08    |
| HIV-positive                          | 238             | 148 (62)        | 90 (38)       |         |
| **Referred from another healthcare facility** |         |                 |               |         |
| No                                    | 1171            | 779 (67)        | 392 (33)      | 0.21    |
| Yes                                   | 460             | 291 (63)        | 169 (37)      |         |
| **Medical devices inserted during the current admission** | | | | <0.01 |
| No                                    | 57              | 51 (89)         | 6 (11)        |         |
| Yes                                   | 1513            | 995 (66)        | 518 (34)      |         |
| **Medical device type**               |                 |                 |               |         |
| Intravenous line                      | 1051            | 712 (68)        | 339 (32)      |         |
| Central venous catheter               | 646             | 384 (59)        | 262 (41)      |         |
| Urinary catheter                      | 527             | 304 (58)        | 223 (42)      |         |
| Drainage port                         | 95              | 63 (66)         | 32 (34)       |         |
| Intra-arterial line                   | 300             | 179 (60)        | 121 (40)      |         |
| Other                                 | 187             | 116 (62)        | 71 (38)       |         |
| **Antibiotics received during the current admission** | | | | 0.02 |
| No                                    | 181             | 107 (59)        | 74 (41)       |         |
| Yes                                   | 1389            | 941 (68)        | 448 (32)      |         |

* Numerators might not add up to the column total because of missing data
* column percentage
* row percentage, interquartile range (IQR)

https://doi.org/10.1371/journal.pone.0271355.t002
negative for the mcr-1 to mcr-5 genes. Whole-genome sequencing was performed on twenty-four colistin-resistant isolates from the laboratory-based surveillance with MIC ≥ 4 μg/ml. For each drug class, at least 79% of isolates had known resistance genes (Table 3). The high proportion of observed phenotypic resistance was mainly due to the presence of resistance genes. Known resistance mechanisms in AMR databases were not observed for colistin and

Table 3. Antimicrobial treatment of *Acinetobacter baumannii* complex (ABC) cases with known patient outcomes in South Africa, 1 August 2018 to 30 September 2019.

| Antimicrobial treatment | Total (N = 1688)* | Alive (N = 1086) | Died (N = 602) |
|-------------------------|------------------|-----------------|---------------|
|                         | n                | n (%)*          | n (%)*        |
| Colistin monotherapy    | 35               | 28 (80)         | 7 (20)        |
| Carbapenem monotherapy  | 219              | 126 (58)        | 93 (42)       |
| Third- or fourth-generation cephalosporin monotherapy | 20 | 17 (85) | 3 (15) |
| Piperacillin-tazobactam monotherapy | 65 | 33 (51) | 32 (49) |
| Aminoglycoside monotherapy | 25       | 17 (68)        | 8 (32)        |
| Carbapenem plus third- or fourth-generation cephalosporin | 21 | 17 (81) | 4 (19) |
| Carbapenem plus aminoglycoside | 40 | 21 (53) | 19 (47) |
| Carbapenem plus aminoglycoside plus piperacillin-tazobactam | 33 | 21 (64) | 12 (36) |
| Carbapenem plus aminoglycoside plus other beta-lactam and beta-lactam inhibitor | 46 | 18 (39) | 28 (61) |
| Colistin plus carbapenem | 167              | 125 (75)        | 42 (25)       |
| Colistin plus carbapenem plus piperacillin-tazobactam | 23 | 16 (70) | 7 (30) |
| Colistin plus carbapenem plus aminoglycoside | 38 | 33 (87) | 5 (13) |
| Colistin plus carbapenem plus aminoglycoside plus other beta-lactam and beta-lactam inhibitor | 44 | 36 (82) | 8 (18) |
| Colistin plus carbapenem plus aminoglycoside plus piperacillin-tazobactam | 27 | 20 (74) | 7 (26) |
| Colistin plus other antimicrobial agents | 43 | 33 (77) | 10 (23) |
| Other antimicrobial agents | 28               | 19 (68)         | 9 (32)        |

* not all treatment regimens were included

*row percentage, carbapenems (doripenem, ertapenem, imipenem, meropenem), 3rd or 4th generation cephalosporins (cefotaxime, ceftazidime, cefepime), aminoglycosides (amikacin, gentamycin, tobramycin), other beta-lactams + beta-lactam inhibitors (ampicillin-sulbactam, amoxicillin-clavulanate, cefotaxime-clavulanate, ceftazidime-clavulanate), other antibiotics (cefotixin, fluoroquinolones (ciprofloxacin, levofloxacin), flagyl, piperacillin, trimethoprim-sulfamethoxazole)

https://doi.org/10.1371/journal.pone.0271355.t003

Fig 2. Antimicrobial susceptibility patterns of *Acinetobacter baumannii* complex (ABC) bloodstream isolates from South Africa from 1 April 2017 to 30 September 2019, n = 2033. Susceptible (S), Intermediate (I) and resistant (R).

https://doi.org/10.1371/journal.pone.0271355.g002
quinolones. For the rest of the antimicrobials, 83% (20/24) of isolates had at least one known resistance gene for all the drugs or drug classes listed in Table 3. The presence of known resistance genes in the remaining four isolates varied; one had resistance genes to aminoglycoside, β-lactams, and sulfonamide; another one had resistance genes to β-lactams and fluoroquinolone, and the last two had resistance genes for only β-lactams. A comparison of the 24 colistin-resistant isolates from South Africa is presented in Table 4. 

Table 4. Antimicrobial minimum inhibitory concentration distribution of Acinetobacter baumannii complex (ABC) bloodstream isolates from South Africa from 1 April 2017 to 30 September 2019.

| Antimicrobial agents (n =) | Number of isolates with MIC value of | MIC<sub>50</sub> | MIC<sub>90</sub> |
|---------------------------|-------------------------------------|----------------|----------------|
|                           | ≤0.5      | 1   | ≤2  | 2   | ≥4  | >8  | 16  | >16 | 32  | >32 | 64  | >64 | 128 | >128 |       |
| Amikacin (2028)            | 440       | 10  | 48  | 1530  |
| Gentamicin (2028)          | 212       | 47  | 1769  |
| Tobramycin (2021)          | 449       | 25  | 1547  |
| Ampicillin/Sulbactam (2017)| 269       | 238 | 1510  |
| Piperacillin (2024)        | 90        | 56  | 1517  |
| Cefazidime (2029)          | 23        | 132 | 129  | 55  | 14  | 1676  |
| Cefepime (2029)            | 34        | 131 | 56   | 14  | 43  | 1751  |
| Imipenem (1736)            | 17        | 3   | 87   | 1629  |
| Meropenem (2019)           | 162       | 57  | 25   | 1775  |
| Doripenem (227)            | 27        | 9   | 191   |
| Ciprofloxacin (2027)       | 215       | 27  | 1732  |
| Levofloxacin (2025)        | 310       | 24  | 725   | 966  |
| Tetracycline (2025)        | 307       | 138 | 1580  |
| Minocycline (2022)         | 642       | 308 | 1072  |
| Trimethoprim/Sulfamethoxazole (2009) | 164    | 1845 | 4/76 | 4/76 |
| Colistin (2001)            | 151       | 1319 | 458  | 8    | 11  | 9    | 6    | 12   | 14   | 13   | 1    | 2    |       |
resistant with 14 colistin susceptible isolates, shows similar proportions of isolates with efflux pump genes (Table 5), indicating colistin resistance may not be mediated by these pumps.

### Discussion

In this report, we analyzed a high number of patients with ABC bacteremia from the national sentinel sites surveillance system and the majority of our cases were isolates of *Acinetobacter baumannii* acquired in hospital settings. Due to the high population density, most of the cases were identified in Gauteng province followed by KwaZulu-Natal and Western Cape. In our study, the highest distribution of ABC isolates was among children less than one-year-old, which is different, compared to a systematic review and meta-analysis by Lyu, where 11 studies were analyzed and population distribution was heterogeneous [23]. Our surveillance data showed a high distribution of ABC among children and is one of the most important findings, which is different from other studies.

---

### Table 5. Summary of resistance genes present in the colistin-resistant *Acinetobacter baumannii* isolates per drug class (n = 24).

| Drug class          | AMR genes detected                                                                 | Drugs                                                                                             | Percentage |
|---------------------|------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|------------|
| Aminoglycosides     | *aac(3)*-Ia, *aph(3’)-Ia, *aph(3’)-Ib, *aph(6)-Id, arma*                           | gentamicin, sisomicin, kanamycin, streptomycin, *arma* (all aminoglycosides, except streptomycin) | 83%        |
|                     | *ant(3’)-IIa*                                                                      | streptomycin & spectinomycin                                                                      | 38%        |
|                     | *ant(2’)-Ia & *aph(3’)*                                                            | Gentamicin, tobramycin, neomycin, paromycin                                                       | 4%         |
| B-lactams           | *bla*$_{ADC-79}$, *bla*$_{OXA-23}$ & *bla*$_{OXA-69}$                              | carbapenems, cephalosporins, penams                                                              | 83%        |
|                     | *bla*$_{NDM-1}$                                                                    | All b-lactams (carbapenems, cephalosporins, cephamycins, penams), except aztreonam              | 79%        |
|                     | *bla*$_{PER-7}$                                                                    | Cephalosporins                                                                                    |            |
|                     | *bla*$_{ADC-4}$, *bla*$_{ADC-58}$, *bla*$_{ADC-68}$, *bla*$_{ADC-79}$, *bla*$_{OXA-51}$, *bla*$_{OXA-56}$ & *bla*$_{OXA-64}$ | Carbapenems, cephalosporins, penams                                                            | 4%         |
| Fluoroquinolones    | *AbaQ*                                                                             | Fluoroquinolones                                                                                  | 92%        |
| Fosfomycin          | *AbaF*                                                                            | Fosfomycin                                                                                        | 88%        |
| Macrolides          | *mphE*                                                                            | Macrolides                                                                                       | 83%        |
| Rifamycin           | *arr-2*                                                                           | Rifamycin                                                                                        | 83%        |
| Sulfonamide         | *sul1*                                                                            | Sulfonamides                                                                                     | 83%        |
|                     | *sul2*                                                                            |                                                                                                   | 88%        |
| Tetracyclines       | *tet(B)*                                                                          | Tetracyclines                                                                                   | 79%        |
| Diaminopyrimidines  | *dfrA1*                                                                           | Trimethoprim                                                                                     | 83%        |
| Bleomycin           | *BRP*                                                                             | Bleomycin only                                                                                    | 79%        |
| Antibiotic target protection | *msrE*                                                                                       | Macrolides, lincomasides, streptogramins, tetracyclines, oxazolidinone, phenicols, pleuromutilin, | 83%        |
| Nucleoside          | *SAT-1*                                                                           | streptothricin                                                                                   | 83%        |
| Phenicol            | *cmlA5*                                                                           | Chloramphenicol                                                                                  | 83%        |
| Acridine dye, disinfecting agents and intercalating dyes | *qacE* (100%)                                                                                       | Quaternary ammonium compounds (QAC)                                                              | 54%        |
| Colistin & Quinolones |                                                                                      |                                                                                                   |            |
| Efflux pump         | *abeM, abeS, adeF, adeG, adeH, adel, adel, adeK & AmvA*                      | Macrolides, lincomasides, streptogramins, tetracyclines, oxazolidinone, phenicols, pleuromutilin, fluoroquinolone, tetracyclines | 100%       |
|                     | *adeA, adeB, adel, aden, aden & adeS*                                             | Macrolides, fluoroquinolones, lincomasides, penems, carbapenems, cephalosporins, tetracyclin, rifamycin, Trimethoprim, Chloramphenicol, glyclycycline, tetracyclines | 92%        |
|                     | *adeC*                                                                            | Glyclycycline, tetracyclines                                                                      | 83%        |

https://doi.org/10.1371/journal.pone.0271355.t005
As indicated, most of our cases were from children less than 1 year and the mortality rate was 36% out of the known number of patients. Similar results were observed in the study by Lyu, where the outcome of infants one month old was 30% with a low difference in the polymyxin compared to the non-polymyxin administration group. Gramatniec identified very few cases of *A. baumannii* bacteremia in neonates with a low mortality rate [3]. Later they noticed an outbreak of ABC with a high colonization rate in the neonatal intensive care unit (NICU) [3]. HIV-positive status was not a significant risk factor for mortality (14%). Similar results were observed in another study on HIV-infected and uninfected adults from Thailand, where *Acinetobacter* spp was the most common cause of bacteraemia in HIV-uninfected patients [24].

A study by Balkhair showed that *A. baumannii* was the most frequent multidrug-resistant isolate with no resistance to colistin however; patients with *A. baumannii* isolates in blood had the worst-case fatality rate [25].

A group from Western Cape demonstrated an increase in numbers of *A. baumannii* isolates in a tertiary hospital from all specimen types and an increase in resistance to all antimicrobials [12]. They performed molecular typing and indicated that four strains were closely related within global clone ST1. All four had undescribed resistance to colistin, not defined previously.

We used a commercial broth microdilution method for colistin testing as recommended by ISO standard 20776–1, CLSI, and EUCAST guidelines. Matuschek evaluated the same method comparing Sensititre and two Micronaut products with ≥ 96% of essential agreement. Our results were based on the equivalent Sensititre method [22]. Using this method, we have identified colistin-resistant isolates, which we screened for chromosomal and plasmid *mcr*-mediated resistance and we have identified none. Although all the colistin-resistant isolates had at least nine efflux pump genes (Table 4), these genes were also equally present in colistin susceptible isolates, indicating little impact of these pumps on colistin resistance. Plasmid-mediated genes are not present and since efflux pumps do not seem to be the cause of the observed resistance, colistin resistance is most likely due to chromosomal mutations that are not present in the databases used for our analysis. However, we should monitor for detection of resistance genes in our isolates as they may present within a low level of resistance with MIC values at the breakpoint and even in susceptible. The role of efflux pumps in colistin resistance is suggested by several studies [12]. Mutations in *kpnEF* and *acrAB*, encoding components of efflux pumps, may lead to a two-fold decrease in the MIC of colistin and increase bacterial survival in the presence of a low concentration of polymyxins [26]. A Western Cape group performed WGS on four colistin-resistant and no *mcr*-1-5 genes were detected. Interestingly they found mutations on transporter family protein 1527N mutation (tripartite ATP-independent periplasmic transporter) not present in colistin-susceptible isolates [12]. In the study by Lin, efflux pump systems contributed to colistin resistance in *A. baumannii*. They found that deletion of *emrAB* gene increased colistin susceptibility, which indicates a role of efflux pumps in colistin susceptibility and is much less characterized compared to AdeABC pumps [27]. The absence of plasmid-mediated and known chromosomal resistance mutations to colistin in the WGS data does not preclude novel or other chromosomal mutations not present in the current databases.

For the treatment of infections due to MDR ABC, combination treatment might be associated with bacterial eradication rather than monotherapy [4]. The same authors indicated that polymyxin B has a better pharmacokinetics and pharmacodynamics profile compared to colistin, however clinical evidence demonstrating pharmacology profiles is lacking; Balkhair et al. surveyed the cause of 30-day mortality and demonstrated that in patients with ABC bacteremia who died, more than 50% were resistant to carbapenems and were adults [25]. Recently, polymyxin B demonstrated better pharmacokinetics and pharmacodynamics profiles and
particularly featuring its active profile [4]. Shi indicated that based on the mortality of *Acinetobacter* pneumonia no evidence supported colistin plus carbapenem therapy over the colistin monotherapy [6].

Having said that colistin resistance is low in this surveillance report however Mendelson et al reported that prevalence in the animal sector is increasing and had reached 17% for *E. coli* in South Africa in the period from 1997–99, with a similar prevalence in 2014. However, mcr-1 was not detected, except in the period after 2015 [28]. Developing a One Health strategy for antibiotics stewardship would prevent the spread of resistance to colistin between sectors [29].

Sentinel sites included in the LARS were limited to tertiary level and academic hospitals; therefore, data generated and reported from the surveillance system does not necessarily represent infections from the whole population and antimicrobial susceptibility patterns from those in the more rural/smaller hospitals. Not all ABC isolates were sent to NICD for further testing. Key missing data such as clinical outcome data limit the generalizability of the findings and results need to be interpreted within the context of general surveillance limitations.

**Conclusion**

Our surveillance data contributed to a better understanding of *A. baumannii* natural cause of disease, the patient’s characteristics particularly distribution among infants and the level of resistance to antibiotics among ABC isolates from the hospital sites. At least two-thirds of the isolates tested phenotypically were multidrug-resistant, with resistance to most antibiotics except for colistin; only 4% of isolates were resistant to colistin.

*Acinetobacter baumannii* is an important nosocomial pathogen posing a serious threat in South Africa, particularly in neonates and infants. *A. baumannii* can readily acquire numerous resistance mechanisms. This multi-drug and extended-drug resistant strains are extremely difficult to treat. Surveillance of this pathogen is important and should continue to track changes in virulence and antibiotic susceptibility profiles; this will ensure the availability of effective drug/s; recommendation of empiric therapy; and implementation of effective infection and prevention control measures.

**Supporting information**

S1 Data. (XLSX)

**Acknowledgments**

The authors thank all staff members of the Antimicrobial Resistance Laboratory and Culture Collection (AMRL-CC), Marshagne Smith, Gloria Molaba, Naseema Bulbulia, Rosah Kganaka, Rubeina Badat, and Agnes Sesoko for phenotypic testing, Boniwe Makwakwa for data capturing, and Nokuthula Linda and Dineo Bogoshi for involvement in molecular testing. The authors thank all the GERMS site investigators.

**Author Contributions**

**Conceptualization:** Olga Perovic.

**Formal analysis:** Olga Perovic, Husna Ismail.

**Funding acquisition:** Olga Perovic.

**Investigation:** Olga Perovic, Vindana Chibabhai, Mohamed Said, Elizabeth Prentice, Jeannette Wadula, Yesholata Mahabeer, K. Swe Swe Han.
Methodology: Olga Perovic.

Resources: Olga Perovic.

Supervision: Olga Perovic.

Validation: Olga Perovic.

Writing – original draft: Olga Perovic.

Writing – review & editing: Adrian Duse, Vindana Chibabhai, Marianne Black, Mohamed Said, Elizabeth Prentice, Jeannette Wadula, Yesholata Mahabeer, K. Swe Swe Han, Ruth Mogokotleng, Wilhelmina Strasheim, Michelle Lowe, Sabelle Jallow, Husna Ismail.

References

1. El-Badawy MF, Abou-Elazm FI, Omar MS, El-Nagar ME, Maghrabi IA. The First Saudi Study Investigating the Plasmid-borne Aminoglycoside and Sulfonamide Resistance among Acinetobacter baumannii Clinical Isolates Genotyped by RAPD-PCR: the Declaration of a Novel Allelic Variant Called aac(6')-SL and Three Novel Mutations in the sulI Gene in the Acinetobacter Plasmid (s). Infect Drug Resist. 2021; 14:4739–56. https://doi.org/10.2147/IDR.S324707 PMID: 34795490

2. Eveillard M, Kempf M, Belmonte O, Pailhories H, Joly-Guillou ML. Reservoirs of Acinetobacter baumannii outside the hospital and potential involvement in emerging human community-acquired infections. Int J Infect Dis. 2013; 17(10):e802–5. https://doi.org/10.1016/j.ijid.2013.03.021 PMID: 23672981

3. Gramatniec A, Silamikeli S, Zahare I, Urtans V, Zahare I, Dimina E, et al. Control of Acinetobacter baumannii outbreak in the neonatal intensive care unit in Latvia: whole-genome sequencing powered investigation and closure of the ward. Antimicrob Resist Infect Control. 2019; 8:84. https://doi.org/10.1186/s13756-019-0537-z PMID: 31143444

4. Kassamali Z, Jain R, Danziger LH. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics. Int J Infect Dis. 2015; 30:125–32. https://doi.org/10.1016/j.ijid.2014.10.014 PMID: 25461655

5. Magiorakos AP, Srinavasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18(3):268–81. https://doi.org/10.1111/j.1469-0691.2011.03570.x PMID: 21793988

6. Vrancianu CO, Gheorghe I, Czobor IB, Chifiriuc MC. Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of Acinetobacter baumannii. Microorganisms. 2020; 8(6). https://doi.org/10.3390/microorganisms8060935 PMID: 32575913

7. WHO. WHO publishes list of bacteria for which new antibiotics are urgently needed; available online at https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. 2017.

8. Chopjitt P, Kerdzin A, Takeuchi D, Hatrongjit R, Boueroy P, Akeda Y, et al. Whole Genome Analysis of Extensively Drug-Resistant Acinetobacter baumannii Clinical Isolates in Thailand. Infect Disord Drug Targets. 2021; 21(5):e270421188042. https://doi.org/10.2174/1871526520999201116201911 PMID: 33200701

9. Shi H, Lee JS, Park SY, Ko Y, Eom JS. Colistin Plus Carbapenem versus Colistin Monotherapy in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Pneumonia. Infect Drug Resist. 2019; 12:3925–34. https://doi.org/10.2147/IDR.S234211 PMID: 31920347

10. Katip W, Utrakul S, Oberdorfer P. A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients: A Propensity Score-Matched Analysis. Antibiotics (Basel). 2020; 9(10). https://doi.org/10.3390/antibiotics9100647 PMID: 32993817

11. Yahav D, Giske CG, Gramatniec A, Abodakpi H, Tam VH, Leibovici L. New beta-Lactam-beta-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020; 34(1). https://doi.org/10.1128/CMR.00115-20 PMID: 33177185

12. Snyman Y, Whitelaw AC, Reuter S, Dramowski A, Maloba MRB, Newton-Foot M. Clonal expansion of colistin-resistant Acinetobacter baumannii isolates in Cape Town, South Africa. Int J Infect Dis. 2020; 91:94–100. https://doi.org/10.1016/j.ijid.2019.11.021 PMID: 31765820
13. Snyman Y, Reuter S, Whitelaw AC, Stein L, Maloba MRB, Newton-Foot M. Characterisation of mcr-4.3 in a colistin-resistant Acinetobacter nosocomialis clinical isolate from Cape Town, South Africa. J Glob Antimicrob Resist. 2021; 25:102–6. https://doi.org/10.1016/j.jgar.2021.03.002 PMID: 33757821

14. Smelikova E, Tkadlec J, Krutova M. How to: screening for mcr-mediated resistance to colistin. Clin Microbiol Infect. 2021.

15. CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 27th 2017.

16. Sambrook J. Molecular Cloning: A Laboratory Manual.

17. Dashti AA. Heat Treatment of Bacteria: A Simple Method of DNA Extraction for Molecular Techniques. Kuwait Medical Journal 2009; 41 (2): 117–122.

18. Rebelo AR, Bortolaia V, Kjeldgaard JS, Pedersen SK, Leekitcharoenphon P, Hansen IM, et al. Multiplex PCR for detection of plasmid-mediated colistin resistance determinants, mcr-1, mcr-2, mcr-3, mcr-4 and mcr-5 for surveillance purposes. Euro Surveill. 2018; 23(6). https://doi.org/10.2807/1560-7917.ES.2018.23.6.17-00672 PMID: 29439754

19. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012; 19(5):455–77. https://doi.org/10.1089/cmb.2012.0021 PMID: 22506699

20. Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, et al. CARD 2020: antibiotic resistance surveillanc e with the comprehensive antibiotic resistance database. Nucleic Acids Res. 2020; 48(D1):D517–D25. https://doi.org/10.1093/nar/gko335 PMID: 31665441

21. Jia B, Raphenya AR, Alcock B, Waglechner N, Guo P, Tsang KK, et al. CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. Nucleic Acids Res. 2017; 45(D1):D566–D73. https://doi.org/10.1093/nar/gkw1004 PMID: 27789705

22. Matuschek E, Ahman J, Webster C, Kahlmeter G. Antimicrobial susceptibility testing of colistin—evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. Clin Microbiol Infect. 2018; 24(8):865–70. https://doi.org/10.1016/j.cmi.2017.11.020 PMID: 29221995

23. Lyu C, Zhang Y, Liu X, Wu J, Zhang J. Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis. BMC Infect Dis. 2020; 20(1):296. https://doi.org/10.1186/s12879-020-05026-2 PMID: 32316926

24. Mootsikapun P. Bacteremia in adult patients with acquired immunodeficiency syndrome in the northeast of Thailand. Int J Infect Dis. 2007; 11(3):226–31. https://doi.org/10.1016/j.ijid.2006.02.010 PMID: 16815065

25. Balkhair A, Al-Muharrmi Z, Al’Adawi B, Al Busaidi I, Taher HB, Al-Siyabi T, et al. Prevalence and 30-day all-cause mortality of carbapenem- and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend. Int J Infect Dis. 2019; 85:10–5. https://doi.org/10.1016/j.ijid.2019.05.004 PMID: 31100418

26. Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes. Clin Microbiol Rev. 2017; 30(2):557–96. https://doi.org/10.1128/CMR.00064-16 PMID: 28275006

27. Lin MF, Lin YY, Lan CY. Contribution of EmrAB efflux pumps to colistin resistance in Acinetobacter baumannii. J Microbiol. 2017; 55(2):130–6. https://doi.org/10.1007/s12275-017-6408-5 PMID: 28120193

28. Mendelson M, Brink A, Gouws J, Mbelle N, Naidoo V, Pople T, et al. The One Health stewardship of colistin as an antibiotic of last resort for human health in South Africa. The Lancet Infectious Diseases. 2018; 18(9):e288–e94. https://doi.org/10.1016/S1473-3099(18)30119-1 PMID: 29673734

29. Goff DA, Kullar R, Goldstein EJC, Gilchrist M, Nathwani D, Cheng AC, et al. A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. The Lancet Infectious Diseases. 2017; 17(2):e56–e63. https://doi.org/10.1016/S1473-3099(16)30386-3 PMID: 27866945